drugset / Trial / NCT06045000
Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants
Phase 1
Completed
8 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
NaSingle-groupOpen-labelBasic science
Summary
The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 μCi) of \[14C\]-DC-806 in urine and feces.
Timeline
- Start
- 2023-09-14
- Primary completion
- 2023-10-02
- Completion
- 2023-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-806 | Unknown | 3.7 mbq | Oral |
Indications
No indication recorded.